Page 28

Please delete lines 20-23 and insert the following language therefore:

B1

GCTGGTGCCGTCTCGAGTGGTGTTTTTTTAATAGG-3' (SEQ ID NO:1) and its complement 5'-CCTATTAAAAAAACACCACTCGAGACGGCACCAGC-3' (SEQ ID NO:2) and SpeI (5'-GGGCGGAGTAACTAGTATGTGTTGGG-3' (SEQ ID NO:3) and its complement 5'-CCCAACACATACTAGTTACTCCGCCC-3' (SEQ ID NO:4). This vector containing both the SpeI

Page 29

Please delete lines 3-4 and insert the following language therefore:

B2

GTGAGCACTAGTCGCCTGGTACCATCCGGACAAAGCC-3' SEQ ID NO:5) and XhoI-E2F1P (5'-GTGAGCCTCGAGCTCGATCCCGCTCCGCCCCCGG-3' SEQ ID NO:6). One hundred

Page 30

Please delete lines 13-16 and insert the following language therefore:

B3

GCTAGGATCCGAAGGGATTGACTTACTCACT-3' (SEQ ID NO: 7) and 5'-GCTAGAATTCCTCTTCATCCTCGTCGTCACT-3' SEQ ID NO:8) and for the E2F-1 promoter in the E4 region (5'-GGTGACGTAGGTTTTAGGGC-3' (SEQ ID NO:9) and 5'-GCCATAACAGTCAGCCTTACC-3' SEQ ID NO:10). PCR was performed using Clontech's

Page 31

Please delete lines 2-3 and insert the following language therefore:

B4 GTGAGCGGATCCGCTCGATCCCGCTCCGCCCCCGG-3' SEQ ID NO:11) and HindIII-E2F1P (5'-GTGAGCAAGCTTCGCCTGGTACCATCCGGACAAAGCC-3' SEQ ID NO:12). One hundred

Page 31

Please delete lines 29-32 and insert the following language therefore:

B5 CGCGGAATTCTTTTGGATTGAAGCCAATATG-3' SEQ ID NO:13) and 3' Bam (5'-CAGTCCCGGTGTCGGATCCGCTCGGAGGAG-3' SEQ ID NO:14), whereas plasmid pXC1 (Microbix) was used as the template in a PCR reaction with primers Bsr-Bam (5'-CTCCTCCGAGCGGATCCGACACCGGGACTG-3' SEQ ID NO:15) and 3' E1A.Xba (5'-

Page 32

Please delete line 1 and insert the following language therefore:

B6 GCGGGACCACCGGGTGTATCTCAGGAGGTG-3' SEQ ID NO:16). The PCR products were

Page 32

Please delete lines 11-12 and insert the following language therefore:

CTCCTCCGAGCGGATCCGACACCGGGACTG-3' SEQ ID NO:15) and 3'E1A.Xba (5'-GCATTCTCTAGACACAGGTG-3' SEQ ID NO:17). The resulting PCR product was purified over a

Page 33

Please delete lines 15-24 and insert the following language therefore:

GGGCGTAACCGAGTAAGATTTGGCC-3' SEQ ID NO:18) and E1Astart.NC (5'-GGCAGATAATATGTCTCATTTTCAGTCCCGG-3' SEQ ID NO:19). The presence of the deletion from nucleotides 922 to 947 within E1A was verified using primers Af-7 (5'-GCTAGGATCCGAAGGGATTGACTTACTCACT-3' SEQ ID NO:20) and Af-5 (5'-GCTAGAATTCCTCTTCATCCTCGTCGTCACT-3' SEQ ID NO:21). The presence of the human E2F1 promoter driving the entire E4 region was confirmed using primers E4.3NCb (5'-GCCATAACAGTCAGCCTTACC-3' SEQ ID NO:22) and Ad5-3' end (5'-GGTGACGTAGGTTTTAGGGC-3' SEQ ID NO:23). The deletion present in the E3 region (dl309) was confirmed using primers E3.C8 (5'-CCTTTATCCAGTGCATTGACTGGG-3' SEQ ID NO.:24) and 3'-E3I (5'-GGAGAAAGTTTGCAGCCAGG-3' SEQ ID NO:25). PCR was performed using

The Commissioner is hereby authorized to charge Applicant's Deposit Account No. 15-0615 for any fees associated with this communication, including extension of time fees that may be due.

Date: February 28, 2002

By: _____
Gregory Giotta, Ph.D.
Reg. No. 32-028

ONYX PHARMACEUTICALS, INC.
3031 Research Drive
Richmond, CA 94806
Telephone: 510-262-8710
Facsimile: 510-222-9758

## APPENDIX 1

Amendments showing modifications

Page 28, lines 20-23

GCTGGTGCCGTCTCGAGTGGTGTTTTTTTAATAGG-3' (SEQ ID NO:1) and its complement 5'-CCTATTAAAAAAACACCACTCGAGACGGCACCAGC-3' (SEQ ID NO:2) and SpeI (5'-GGGCGGAGTAACTAGTATGTGTTGGG-3' (SEQ ID NO:3) and its complement 5'-CCCAACACATACTAGTTACTCCGCCC-3' (SEQ ID NO:4). This vector containing both the SpeI

Page 29, lines 3-4

GTGAGCACTAGTCGCCTGGTACCATCCGGACAAAGCC-3' SEQ ID NO:5) and XhoI-E2F1P (5'-GTGAGCCTCGAGCTCGATCCCGCTCCGCCCCCGG-3' SEQ ID NO:6). One hundred

Page 30, lines 13-16

GCTAGGATCCGAAGGGATTGACTTACTCACT-3' (SEQ ID NO: 7) and 5'-GCTAGAATTCCTCTTCATCCTCGTCGTCACT-3' SEQ ID NO:8) and for the E2F-1 promoter in the E4 region (5'-GGTGACGTAGGTTTTAGGGC-3' (SEQ ID NO:9) and 5'-GCCATAACAGTCAGCCTTACC-3' SEQ ID NO:10). PCR was performed using Clontech's

Page 31, lines 2-3

GTGAGCGGATCCGCTCGATCCCGCTCCGCCCCCGG-3' SEQ ID NO:11) and HindIII-E2F1P (5'-GTGAGCAAGCTTCGCCTGGTACCATCCGGACAAAGCC-3' SEQ ID NO:12). One hundred

Page 31, lines 29-32

CGCGGAATTCTTTTGGATTGAAGCCAATATG-3' SEQ ID NO:13) and 3' Bam (5'-CAGTCCCGGTGTCGGATCCGCTCGGAGGAG-3' SEQ ID NO:14), whereas plasmid pXC1 (Microbix) was used as the template in a PCR reaction with primers Bsr-Bam (5'-CTCCTCCGAGCGGATCCGACACCGGGACTG-3' SEQ ID NO:15) and 3' E1A.Xba (5'-

Page 32, line 1

GCGGGACCACCGGGTGTATCTCAGGAGGTG-3' SEQ ID NO:16). The PCR products were

Page 32, lines 11-12

CTCCTCCGAGCGGATCCGACACCGGGACTG-3' SEQ ID NO:15) and 3'E1A.Xba (5'-GCATTCTCTAGACACAGGTG-3' SEQ ID NO:17). The resulting PCR product was purified over a

Page 33, lines 15-24

GGGCGTAACCGAGTAAGATTTGGCC-3' SEQ ID NO:18) and E1Astart.NC (5'-GGCAGATAATATGTCTCATTTTCAGTCCCGG-3' SEQ ID NO:19). The presence of the deletion from nucleotides 922 to 947 within E1A was verified using primers Af-7 (5'-GCTAGGATCCGAAGGGATTGACTTACTCACT-3' SEQ ID NO:20) and Af-5 (5'-GCTAGAATTCCTCTTCATCCTCGTCGTCACT-3' SEQ ID NO:21). The presence of the human E2F1 promoter driving the entire E4 region was confirmed using primers E4.3NCb (5'-GCCATAACAGTCAGCCTTACC-3' SEQ ID NO:22) and Ad5-3' end (5'-GGTGACGTAGGTTTTAGGGC-3' SEQ ID NO:23). The deletion present in the E3 region (dl309) was confirmed using primers E3.C8 (5'-CCTTTATCCAGTGCATTGACTGGG-3' SEQ ID NO.:24) and 3'-E3I (5'-GGAGAAAGTTTGCAGCCAGG-3' SEQ ID NO:25). PCR was performed using